ZYUS Life Sciences Secures Second U.S. Patent for Cannabichromene-Based Pain Management Therapy
核心洞察
ZYUS Life Sciences received U.S. Patent No. 12,616,704 for a novel cannabichromene formulation targeting chronic and neuropathic pain (搜索) management.
The patent strengthens the company's intellectual property portfolio and supports development of their second drug candidate for peripheral neuropathy (搜索) conditions.
Investigational New Drug-enabling studies have been completed for the patented formulation, positioning the company to initiate clinical trials in the United States.
ZYUS Life Sciences Corporation (搜索) announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,616,704, entitled "Cannabichromene Formulation for Pain Management," marking the clinical-stage company's second U.S. patent in pain management. The patent covers a novel, non-intoxicating approach to pain management and is held by ZYUS' wholly owned subsidiary, ZYUS Life Sciences Inc.
Patent Strengthens Cannabinoid-Based Pipeline
The newly issued patent relates to ZYUS' second drug candidate and expands the company's pipeline of novel, proprietary, non-opioid therapies. The patent supports ongoing clinical research targeting neuropathic pain (搜索), including peripheral neuropathy (搜索) conditions such as diabetic and cancer-related neuropathies. These indications align with those covered under the company's first patent, reinforcing ZYUS' focused approach to pain management.
The patent is based on International Patent Application No. PCT/CA2021/050430 and provides intellectual property protection for cannabichromene (CBC), whether used as monotherapy or within the company's lead drug product, Trichomylin® softgel capsules. The company's first U.S. patent supports Trichomylin® softgel capsules, a proprietary fixed-dose combination that delivers a balanced ratio of cannabinoids, including CBC.
Clinical Development Progress
ZYUS has completed Investigational New Drug (IND)-enabling studies for the second drug candidate covered by the new patent, positioning the company to potentially initiate clinical trials in the United States. The patent provides additional intellectual property protection alongside potential regulatory exclusivity for CBC, subject to regulatory determination by the U.S. Food and Drug Administration (搜索) at the time of marketing authorization.
The company is currently advancing Phase 2 clinical development of Trichomylin® softgel capsules and preparing Investigational New Drug applications with the U.S. FDA.
Strategic Focus on Non-Opioid Alternatives
"The issuance of this U.S. patent further validates our commitment to advancing a differentiated portfolio of novel non-opioid pain drugs," said Brent Zettl, President and CEO of ZYUS. "We remain focused on developing innovative treatment options to address significant unmet needs in chronic and neuropathic pain (搜索)."
ZYUS Life Sciences is focused on the development and commercialization of novel cannabinoid-based pharmaceutical drug candidates for pain management. The company aims to secure intellectual property protection for its innovative therapies while pursuing regulatory approval of non-opioid-based pharmaceutical solutions as alternatives to current pain management therapies such as opioids.